Contents

Current Pharmaceutical Design, Volume 18 - Number 25

Editorial

Editorial: [Hot Topics: The Blood Brain Barrier in Stroke]

, 18(25): 3613 - 3614

Cesar V. Borlongan


DOI: 10.2174/138161212802002751




Breaking the Barrier in Stroke: What Should we Know? A Mini-Review

, 18(25): 3615 - 3623

Cesar V. Borlongan, Antonio A. Rodrigues and Maria Carolina Oliveira


DOI: 10.2174/138161212802002670




Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke

, 18(25): 3624 - 3644

Patrick T. Ronaldson and Thomas P. Davis


DOI: 10.2174/138161212802002625




Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier

, 18(25): 3645 - 3648

Ji Hae Seo, Shuzhen Guo, Josephine Lok, Deepti Navaratna, Michael J. Whalen, Kyu-Won Kim and Eng H. Lo


DOI: 10.2174/138161212802002742




Mechanisms of Endogenous Endothelial Repair in Stroke

, 18(25): 3649 - 3652

Toru Yamashita and Koji Abe


DOI: 10.2174/138161212802002832




The Role of Pericytes in Blood-Brain Barrier Function and Stroke

, 18(25): 3653 - 3662

Shuo Liu, Dritan Agalliu, Chuanhui Yu and Mark Fisher


DOI: 10.2174/138161212802002706




Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection

, 18(25): 3663 - 3669

Naoki Tajiri, Tsz Lau, Loren E. Glover, Kazutaka Shinozuka, Yuji Kaneko, Harry van Loveren and Cesar V. Borlongan


DOI: 10.2174/138161212802002724




Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy

, 18(25): 3670 - 3676

Cesar V. Borlongan, Loren E. Glover, P. R. Sanberg and David C. Hess


DOI: 10.2174/138161212802002841




Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke

, 18(25): 3677 - 3684

Tauheed Ishrat, Sahar Soliman, Weihua Guan, Mihaela Saler and Susan C. Fagan


DOI: 10.2174/138161212802002779




Tracking Stem Cells for Cellular Therapy in Stroke

, 18(25): 3685 - 3693

Nathan C. Manley and Gary K. Steinberg


DOI: 10.2174/138161212802002643




A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke

, 18(25): 3694 - 3703

Paul A. Lapchak


DOI: 10.2174/138161212802002652




Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke

, 18(25): 3704 - 3720

Xiaoming Hu, Meijuan Zhang, Rehana K Leak, Yu Gan, Peiying Li, Yanqin Gao and Jun Chen


DOI: 10.2174/138161212802002715




CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke

, 18(25): 3721 - 3730

Sunghee Cho


DOI: 10.2174/138161212802002760




Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells

, 18(25): 3731 - 3734

Yuji Kaneko, Naoki Tajiri, Kazutaka Shinozuka, Loren E. Glover, Nathan L. Weinbren, Lourdes Cortes and Cesar V. Borlongan


DOI: 10.2174/138161212802002733




Editorial

Editorial: Advances in Epithelial Ovarian Cancer Therapy

, 18(25): 3735 - 3740

Judith R. Kroep


DOI: 10.2174/138161212802002788




Review of Dose-intense Platinum and/or Paclitaxel Containing Chemotherapy in Advanced and Recurrent Epithelial Ovarian Cancer

, 18(25): 3741 - 3753

Ingrid A. Boere and Maria E.L. van der Burg


DOI: 10.2174/138161212802002634




Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer

, 18(25): 3754 - 3769

Bradley J. Monk, Heather Dalton, Ivor Benjamin and Adnan Tanovic


DOI: 10.2174/138161212802002814




The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas

, 18(25): 3770 - 3774

Anna V. Tinker and Karen Gelmon


DOI: 10.2174/138161212802002823




The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer

, 18(25): 3775 - 3783

Judith R. Kroep and Johan W.R. Nortier


DOI: 10.2174/138161212802002689




Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance

, 18(25): 3784 - 3792

Arne R.M. van der Bilt, Ate G.J. van der Zee, Elisabeth G.E. de Vries, Steven de Jong, Hetty Timmer- Bosscha, Klaske A. ten Hoor, Wilfred F.A. den Dunnen, Harry Hollema and Anna K.L. Reyners


DOI: 10.2174/138161212802002661




Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence

, 18(25): 3793 - 3803

Stefaan Mulier, Jean-Pierre Claes, Vincent Dierieck, Jean-Olivier Amiel, Jean-Philippe Pahaut, Luc Marcelis, Fabienne Bastin, Denis Vanderbeeken, Claude Finet, Sophie Cran and Thierry Velu


DOI: 10.2174/138161212802002616




Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen

, 18(25): 3804 - 3811

Renee Vermeij, Ninke Leffers, Cornelis J. Melief, Toos Daemen and Hans W. Nijman


DOI: 10.2174/138161212802002805




Role of Farletuzumab in Epithelial Ovarian Carcinoma

, 18(25): 3812 - 3815

Danijela Jelovac and Deborah K. Armstrong


DOI: 10.2174/138161212802002698




Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer

, 18(25): 3816 - 3827

Eveline M. Dijkgraaf, Marij J.P. Welters, Johan W.R. Nortier, Sjoerd H. van der Burg and Judith R. Kroep


DOI: 10.2174/138161212802002797




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science